With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Discover Baker Brothers' Q3 2025 portfolio shifts—see top biotech stock picks, strategic increases, and key holdings.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The era of AI agents,” as Microsoft claimed at its recent Build 2025 conference, was meant to mark a new era of self-driven ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK ...

“TED is 5 times more prevalent in women, and because of that, men are often overlooked for the diagnosis,” Nijm said. The ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...

North Carolina was busy again this year. Let’s dive into the state of the “top” business state — from Apple to SAS, Epic ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Hub101 held its 2024 Demo Day for its Idea2Do program where several companies pitched their ideas for startups. Cal Lutheran ...